| |
SVR Rates Are The Same in HIV/HCV Coinfected as in Mono-infected Patients !
|
| |
| |
Download the PDF here
Does HIV remain a risk factor for achieving sustained virological response (SVR) under DAA-based modern HCV therapy?
Clinical Infectious Diseases Advance Access published August 18, 2014
Jurgen Kurt Rockstroh
"In conclusion, similar cure rates under modern DAA-based HCV therapy in HIV/HCV coinfection should prompt increased uptake of these improved HCV therapies in a patient population with an even in the ART era higher risk for liver fibrosis progression."
Here the 4 most recent DAA studies in HIV/HCV connected patients with 88-92% SVR rates, and ongoing in coinfection are additional studies including -
BMS' ALLY-2 with Sofosbuvir+Daclatasvir - Phase III HIV/HCV Co-Infection Daclatasvir (DCV)+ Sofosbuvir (SOF).......in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6)
IAC: High SVR12 With Sofosbuvir/Ribavirin in HCV/HIV-Coinfected: PHOTON-2 (07/21/14)
IAC: TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 (07/21/14)
ERADICATE STUDY: SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 INFECTION IN PATIENTS COINFECTED WITH HIV (Interim results) 100% SVR rate
http://www.natap.org/2014/EASL/EASL_05.htm
90-97% SVR rate - ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY......http://www.natap.org/2014/EASL/EASL_15.htm
|
|
| |
| |
|
|
|
